CONSHOHOCKEN, PA — AdaptHealth Corp. (NASDAQ: AHCO) reported a $168.2 million third-quarter loss after recording a $184.8 million goodwill impairment, while cutting its 2026 free cash flow forecast despite double-digit revenue growth as the home medical equipment provider restructures its operations and prepares to sell its diabetes business.
The company reported revenue of $745.6 million for the quarter ended Sept. 30, 2026, up 10.9% from $672.4 million a year earlier. Organic revenue increased 12.8%, with growth across all reportable segments.
The quarterly loss compared with net income of $10.2 million in the prior-year period. The goodwill impairment, a noncash accounting charge, was the principal factor behind the earnings reversal.
Adjusted earnings before interest, taxes, depreciation and amortization fell 2.9% to $141.9 million from $146.1 million, indicating that operating profitability did not keep pace with revenue growth.
AdaptHealth also reported a substantial decline in cash generation during the first nine months of 2026.
Operating cash flow totaled $395.6 million, down from $418.6 million during the comparable period in 2025. Free cash flow dropped to $2.6 million from $140.1 million.
The company reduced its full-year free cash flow guidance to $50 million to $75 million, compared with its previous forecast of $80 million to $120 million.
At the same time, AdaptHealth raised its revenue outlook to $2.88 billion to $2.90 billion from $2.85 billion to $2.89 billion. It also increased its adjusted EBITDA forecast to $510 million to $525 million from $490 million to $520 million.
The revised revenue and adjusted EBITDA forecasts exclude the Diabetes Health business, while free cash flow guidance includes both continuing and discontinued operations.
The results come as AdaptHealth moves toward completing the $235 million cash sale of its Diabetes Health business, a transaction intended to concentrate operations on Sleep Health, Respiratory Health and Wellness-at-Home services.
The proposed sale has cleared the waiting period under the Hart-Scott-Rodino antitrust review process. AdaptHealth expects the transaction to close in early 2027, subject to remaining regulatory approvals and customary conditions.
The divestiture would further narrow the company’s business portfolio as management works to improve operating efficiency and profitability.
AdaptHealth also reported progress under an exclusive capitated agreement with a large national integrated delivery network.
Under capitated arrangements, healthcare providers generally receive predetermined payments for covered services rather than reimbursement for each individual service delivered, creating incentives to control utilization and operating costs.
During the agreement’s second full quarter, utilization declined from peak levels and labor expenses decreased, improving the contract’s profitability compared with the preceding quarter.
“Our capitated partnership made a positive contribution to enterprise Adjusted EBITDA, driven by a tighter labor model and lower costs to serve,” Chief Executive Officer Suzanne Foster said.
The company expanded its healthcare partnerships during the quarter, signing preferred-provider agreements with four health systems and adding two smaller capitated arrangements with regional health plans, including one new agreement and one expansion.
Those contracts broaden AdaptHealth’s relationships with healthcare organizations as it shifts toward more integrated home-based medical services.
Digital patient engagement also increased. Registered users of the company’s myAPP platform exceeded 615,000, approximately 88% above the year-end 2025 level.
AdaptHealth completed more than 12,600 patient scans using an artificial intelligence-powered mask-fitting tool, part of its efforts to incorporate digital technology into patient services.
Foster characterized the company’s performance as evidence of improving operations despite the financial pressures associated with its restructuring.
“The business is stabilizing as we work through a period of transformation, and we look forward to carrying that momentum into 2027,” she said.
The combination of rising revenue, declining adjusted operating earnings and sharply reduced free cash flow underscores the financial pressures AdaptHealth faces as it reorganizes its business.
The pending diabetes divestiture and expanding healthcare partnerships will be central to the company’s efforts to improve profitability and cash generation heading into 2027.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.
